Proactive Clinical Research — research payments reported

By program year

3 rows

Year	Kind	Amount	Payments
2025	Research	$291,653	30
2024	Research	$264,253	12
2023	Research	$156,618	7

Breakdown

Who paid Research payments · program years 2023–2025

Novartis Pharmaceuticals Corporation $344,159 17 payments
Pfizer Inc. $170,508 18 payments
GlaxoSmithKline, LLC. $135,583 10 payments
AstraZeneca Pharmaceuticals LP $58,597 2 payments
Ipsen Pharma SAS $2,076 1 payment
Amgen Inc. $1,600 1 payment

Studies the money was for Research payments · program years 2023–2025

A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) $164,465 5 payments
A Phase 2, Randomized, Double-Blind, Multi-Dose, Dose Finding Study to $135,583 10 payments
A Phase 3 Master Protocol to Evaluate the Safety Tolerability and Immunogenicity of Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Adults at High Risk of Severe RSV Disease $115,336 9 payments
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardiovascular disease $92,405 3 payments
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi $50,786 4 payments
A Phase 3 Multicenter Parallelgroup Openlabel Study to Evaluate the Safety Tolerability and Immunogenicity of Respiratory Syncytial Virus Prefusion F Subunit Vaccine When Coadministered With Herpes Zoster Subunit Vaccine in Adults 50 Years of Age $39,223 7 payments
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD $36,502 5 payments
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event $29,613 1 payment
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS $28,984 1 payment
An Interventional Phase 23 Adaptive Multicenter Randomized Doubleblind Study to Investigate Efficacy and Safety of Oral Sisunatovir Compared With Placebo in Nonhospitalized Symptomatic Adults With Respiratory Syncytial Virus Infection Who Are at Risk of Progression to Severe Illness $15,950 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.